Clinical trial
A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)
NCT00724048 is registered in ClinicalTrials.gov with Teva Branded Pharmaceutical Products R&D, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 24, 2008
- Completion date
- July 26, 2010
- Enrollment
- 227 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.